A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

2013 ◽  
Vol 73 (1) ◽  
pp. 103-111 ◽  
Author(s):  
J. F. Grippo ◽  
W. Zhang ◽  
D. Heinzmann ◽  
K. H. Yang ◽  
J. Wong ◽  
...  
Keyword(s):  
Phase I ◽  
Metastatic Melanoma ◽  
Multiple Dose ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Multiple Dose Pharmacokinetics

scholarly journals A phase I, open-label study of pasireotide in patients with BRAF- and NRAS-wild type, unresectable and or metastatic melanoma

2016 ◽  
Vol 27 ◽  
pp. vi394
Author(s):  
R. Dummer ◽  
O.A. Michielin ◽  
M. Nägeli ◽  
S.M. Goldinger ◽  
F. Campigotto ◽  
...  
Keyword(s):  
Phase I ◽  
Metastatic Melanoma ◽  
Wild Type ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors

2015 ◽  
Vol 26 (3) ◽  
pp. 350-358 ◽  
Author(s):  
Laurence Ridoux ◽  
Dorothée R. Sémiond ◽  
Carine Vincent ◽  
Hélène Fontaine ◽  
Christine Mauriac ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Open Label ◽  
Open Label Study ◽  
Label Study

A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 3001-3001 ◽  
Author(s):  
Q. Chu ◽  
L. Goldstein ◽  
N. Murray ◽  
E. Rowinsky ◽  
M. Cianfrocca ◽  
...  
Keyword(s):  
Phase I ◽  
Cancer Patients ◽  
Open Label ◽  
Open Label Study ◽  
Label Study
Sign in / Sign up

Export Citation Format

Share Document